CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

(19)

(11)

EP 2 462 147 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	18.03.2015 Bulletin 2015/12

(45)	Mention of the grant of the patent:
	12.11.2014 Bulletin 2014/46

(21)	Application number: 09781527.8

(22)	Date of filing: 05.08.2009

(51)

International Patent Classification (IPC):

C07D 498/04^(2006.01)
C07F 7/08^(2006.01)
A61K 31/695^(2006.01)
A61P 25/24^(2006.01)

C07D 498/18^(2006.01)
A61K 31/4745^(2006.01)
A61P 1/06^(2006.01)

(86)	International application number:
	PCT/EP2009/060168

(87)	International publication number:
	WO 2011/015241 (10.02.2011 Gazette 2011/06)

(54)	CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS KONFORMATIONSEINGESCHRÄNKTE VOLLSYNTHETSCHE MAKROCYCLISCHE VERBINDUNGEN COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES, À CONFORMATION CONTRAINTE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
	Designated Extension States:
	AL BA RS

(43)	Date of publication of application:
	13.06.2012 Bulletin 2012/24

(73)	Proprietor: Polyphor AG
	4123 Allschwil (CH)

(72)	Inventors:
	OBRECHT, Daniel CH-4112 Bättwil (CH) ERMERT, Philipp CH-4123 Allschwil (CH) OUMOUCH, Said F-68200 Mulhouse (FR) LACH, Franck F-51400 Les Grandes Loges (FR) LUTHER, Anatol 79589 Binzen (DE) MARX, Karsten CH-4055 Basel (CH) MÖHLE, Kerstin CH-8907 Wettswil (CH)

(74)	Representative: Braun, André jr.
	Braunpat Braun Eder AG Reussstrasse 22 4054 Basel 4054 Basel (CH)

(56)

References cited: :

EP-A2- 0 807 639

WO-A2-01/77113

CHEN ET AL.: "Synthesis of Novel 4-tert-Alkyl Ether Proline-Based 16- and 17-Membered Macrocyclic Compounds" J. ORG. CHEM., vol. 67, 2002, pages 2730-2733, XP002580115
ARASAPPAN ET AL.: "Novel Dipeptide Macrocycles from 4-Oxo, -Thio, and -Amino-Substituted Proline Derivatives" J. ORG. CHEM., vol. 67, 2002, pages 3923-3926, XP002580116
CHEN ET AL.: "NOVEL POTENT HEPATITIS C VIRUS NS3 SERINE PROTEASE INHIBITORS DERIVED FROM PROLINE-BASED MACROCYCLES" J. MED. CHEM., vol. 49, 7 January 2006 (2006-01-07), pages 995-1005, XP002447441
MARSAULT ET AL.: "Discovery of a new class of macrocylic antagonists to the human motilin receptor" J. MED. CHEM., vol. 49, no. 24, 1 January 2006 (2006-01-01), pages 7190-7197, XP002484961 [retrieved on 2006-11-07]
MARSAULT ET AL: "Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids" BIOORG. MED. CHEM. LETT., vol. 17, no. 15, 1 August 2007 (2007-08-01), pages 4187-4190, XP022144671
ROBINSON ET AL.: "The design, structures and therapeutic potential of protein epitope mimetics" DRUG DISCOVERY TODAY, vol. 13, no. 21-22, 1 November 2008 (2008-11-01), pages 944-951, XP025574298 [retrieved on 2008-09-11]


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).